An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients

Summary

A study to compare the efficacy of GW-1000-02 \[named Sativex® in Canada and also named Sativex® Oromucosal Spray\] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.

Timeline

Start

2001-05

Primary completion

2002-07

Completion

2002-07

Outcome

Missed primary endpoint

registry GW-1000-02 vs Placebo; p = 0.124; Estimated mean treatment difference -5.93 (95% CI -13.52 to 1.65); ANCOVA NCT01610700 ↗

Publications

• Results Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004 Aug;10(4):434-41. doi: 10.1191/1352458504ms1082oa.

Drugs

Indications